{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:47:06Z","timestamp":1793677626510,"version":"4.5.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Natural Science Foundation of Inner Mongolia Autonomous Region, China","award":["2014BS0807"],"award-info":[{"award-number":["2014BS0807"]}]},{"name":"Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region, China"},{"name":"the Innovative Talents Group Foundation of Nephrology Department, Affiliated Hospital, Inner Mongolia Medical University of the Fifth Inner Mongolia 'Prairie Meritocrat' Project"},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7162193"],"award-info":[{"award-number":["7162193"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Doctorial Scientific Research Starting Foundation of the Affiliated Hospital, Inner Mongolia Medical University","award":["NYFYBS2015013"],"award-info":[{"award-number":["NYFYBS2015013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00774-019-00989-y","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T13:38:14Z","timestamp":1548941894000},"page":"805-814","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats"],"prefix":"10.1007","volume":"37","author":[{"given":"Jianrong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongying","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingnan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9236-5546","authenticated-orcid":false,"given":"Yan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"989_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/ger.12093","volume":"32","author":"JE Iglesias","year":"2015","unstructured":"Iglesias JE, Salum FG, Figueiredo MA, Cherubini K (2015) Important aspects concerning alendronate-related osteonecrosis of the jaws: a literature review. Gerodontology 32:169\u2013178","journal-title":"Gerodontology"},{"key":"989_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00774-014-0591-9","volume":"33","author":"Y Saita","year":"2015","unstructured":"Saita Y, Ishijima M, Mogami A, Kubota M, Baba T et al (2015) The incidence of and risk factors for developing atypical femoral fractures in Japan. J Bone Miner Metab 33:311\u2013318","journal-title":"J Bone Miner Metab"},{"key":"989_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jbmr.1998","volume":"29","author":"E Shane","year":"2014","unstructured":"Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD et al (2014) Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 29:1\u201323","journal-title":"J Bone Miner Res"},{"key":"989_CR4","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s00223-009-9263-5","volume":"85","author":"R Armamento-Villareal","year":"2009","unstructured":"Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, Novack D (2009) Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 85:37\u201344","journal-title":"Calcif Tissue Int"},{"key":"989_CR5","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1210\/jc.2004-0952","volume":"90","author":"CV Odvina","year":"2005","unstructured":"Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY (2005) Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294\u20131301","journal-title":"J Clin Endocrinol Metab"},{"key":"989_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1463-1326.2007.00801.x","volume":"10","author":"Y Tamura","year":"2008","unstructured":"Tamura Y, Watada H, Sato F, Kumashiro N, Sakurai Y, Hirose T, Tanaka Y, Kawamori R (2008) Effects of metformin on peripheral insulin sensitivity and intracellular lipid contents in muscle and liver of overweight Japanese subjects. Diabetes Obes Metab 10:733\u2013738","journal-title":"Diabetes Obes Metab"},{"key":"989_CR7","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.2337\/diacare.16.10.1387","volume":"16","author":"D Giugliano","year":"1993","unstructured":"Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, D\u2019Onofrio F (1993) Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16:1387\u20131390","journal-title":"Diabetes Care"},{"key":"989_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1902\/jop.2015.140646","volume":"86","author":"AR Pradeep","year":"2015","unstructured":"Pradeep AR, Nagpal K, Karvekar S, Patnaik K, Naik SB, Guruprasad CN (2015) Platelet-rich fibrin with 1% metformin for the treatment of intrabony defects in chronic periodontitis: a randomized controlled clinical trial. J Periodontol 86:729\u2013737","journal-title":"J Periodontol"},{"key":"989_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/j.1463-1326.2011.01461.x","volume":"13","author":"JL Borges","year":"2011","unstructured":"Borges JL, Bilezikian JP, Jones-Leone AR, Acusta AP, Ambery PD, Nino AJ, Grosse M, Fitzpatrick LA, Cobitz AR (2011) A randomized, parallel group, double-blind, multicentre study comparing the efficacy and safety of Avandamet (rosiglitazone\/metformin) and metformin on long-term glycaemic control and bone mineral density after 80\u00a0weeks of treatment in drug-naive type 2 diabetes mellitus patients. Diabetes Obes Metab 13:1036\u20131046","journal-title":"Diabetes Obes Metab"},{"key":"989_CR10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1359\/jbmr.080323","volume":"23","author":"LJ Melton 3rd","year":"2008","unstructured":"Melton LJ 3rd, Leibson CL, Achenbach SJ, Therneau TM, Khosla S (2008) Fracture risk in type 2 diabetes: update of a population-based study. J Bone Miner Res 23:1334\u20131342","journal-title":"J Bone Miner Res"},{"key":"989_CR11","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s00125-005-1786-3","volume":"48","author":"P Vestergaard","year":"2005","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2005) Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48:1292\u20131299","journal-title":"Diabetologia"},{"key":"989_CR12","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1002\/jcb.23206","volume":"112","author":"QG Mai","year":"2011","unstructured":"Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC (2011) Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 112:2902\u20132909","journal-title":"J Cell Biochem"},{"key":"989_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejphar.2010.02.051","volume":"635","author":"Y Gao","year":"2010","unstructured":"Gao Y, Li Y, Xue J, Jia Y, Hu J (2010) Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol 635:231\u2013236","journal-title":"Eur J Pharmacol"},{"key":"989_CR14","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.diabres.2013.05.016","volume":"101","author":"MJ Tolosa","year":"2013","unstructured":"Tolosa MJ, Chuguransky SR, Sedlinsky C, Schurman L, McCarthy AD, Molinuevo MS, Cortizo AM (2013) Insulin-deficient diabetes-induced bone microarchitecture alterations are associated with a decrease in the osteogenic potential of bone marrow progenitor cells: preventive effects of metformin. Diabetes Res Clin Pract 101:177\u2013186","journal-title":"Diabetes Res Clin Pract"},{"key":"989_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1359\/jbmr.090732","volume":"25","author":"MS Molinuevo","year":"2010","unstructured":"Molinuevo MS, Schurman L, McCarthy AD, Cortizo AM, Tolosa MJ, Gangoiti MV, Arnol V, Sedlinsky C (2010) Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J Bone Miner Res 25:211\u2013221","journal-title":"J Bone Miner Res"},{"key":"989_CR16","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.bbrc.2008.08.034","volume":"375","author":"I Kanazawa","year":"2008","unstructured":"Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T (2008) Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun 375:414\u2013419","journal-title":"Biochem Biophys Res Commun"},{"key":"989_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejphar.2006.02.030","volume":"536","author":"AM Cortizo","year":"2006","unstructured":"Cortizo AM, Sedlinsky C, McCarthy AD, Blanco A, Schurman L (2006) Osteogenic actions of the anti-diabetic drug metformin on osteoblasts in culture. Eur J Pharmacol 536:38\u201346","journal-title":"Eur J Pharmacol"},{"key":"989_CR18","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1007\/s00198-018-4637-z","volume":"29","author":"AK Nordklint","year":"2018","unstructured":"Nordklint AK, Almdal TP, Vestergaard P, Lundby-Christensen L, Boesgaard TW et al (2018) The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporos Int 29:2517\u20132526","journal-title":"Osteoporos Int"},{"key":"989_CR19","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00198-013-2371-0","volume":"24","author":"J Jeyabalan","year":"2013","unstructured":"Jeyabalan J, Viollet B, Smitham P, Ellis SA, Zaman G, Bardin C, Goodship A, Roux JP, Pierre M, Chenu C (2013) The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healing. Osteoporos Int 24:2659\u20132670","journal-title":"Osteoporos Int"},{"key":"989_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.bone.2004.07.015","volume":"36","author":"G Ortoft","year":"2005","unstructured":"Ortoft G, Andreassen TT, Oxlund H (2005) Growth hormone can reverse glucocorticoid-induced low bone turnover on cortical but not on cancellous bone surfaces in adult Wistar rats. Bone 36:123\u2013133","journal-title":"Bone"},{"key":"989_CR21","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/S8756-3282(00)00375-6","volume":"27","author":"L Mosekilde","year":"2000","unstructured":"Mosekilde L, Thomsen JS, Mackey MS, Phipps RJ (2000) Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27:639\u2013645","journal-title":"Bone"},{"key":"989_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.taap.2009.11.026","volume":"243","author":"MP Quaile","year":"2010","unstructured":"Quaile MP, Melich DH, Jordan HL, Nold JB, Chism JP, Polli JW, Smith GA, Rhodes MC (2010) Toxicity and toxicokinetics of metformin in rats. Toxicol Appl Pharmacol 243:340\u2013347","journal-title":"Toxicol Appl Pharmacol"},{"key":"989_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1002\/jbmr.5650020617","volume":"2","author":"AM Parfitt","year":"1987","unstructured":"Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595\u2013610","journal-title":"J Bone Miner Res"},{"key":"989_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S2213-8587(13)70045-7","volume":"1","author":"MJ Seibel","year":"2013","unstructured":"Seibel MJ, Cooper MS, Zhou H (2013) Glucocorticoid-induced osteoporosis: mechanisms, management, and future perspectives. Lancet Diabetes Endocrinol 1:59\u201370","journal-title":"Lancet Diabetes Endocrinol"},{"key":"989_CR25","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S8756-3282(02)00807-4","volume":"31","author":"PA Hulley","year":"2002","unstructured":"Hulley PA, Conradie MM, Langeveldt CR, Hough FS (2002) Glucocorticoid-induced osteoporosis in the rat is prevented by the tyrosine phosphatase inhibitor, sodium orthovanadate. Bone 31:220\u2013229","journal-title":"Bone"},{"key":"989_CR26","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1136\/annrheumdis-2013-203249","volume":"72","author":"N Duru","year":"2013","unstructured":"Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72:1905\u20131913","journal-title":"Ann Rheum Dis"},{"key":"989_CR27","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276","journal-title":"Osteoporos Int"},{"key":"989_CR28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/acr.20295","volume":"62","author":"JM Grossman","year":"2010","unstructured":"Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:1515\u20131526","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"989_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","volume":"5","author":"AA Reszka","year":"2003","unstructured":"Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5:65\u201374","journal-title":"Curr Rheumatol Rep"},{"key":"989_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/art.30135","volume":"63","author":"SL Teitelbaum","year":"2011","unstructured":"Teitelbaum SL, Seton MP, Saag KG (2011) Should bisphosphonates be used for long-term treatment of glucocorticoid-induced osteoporosis? Arthritis Rheum 63:325\u2013328","journal-title":"Arthritis Rheum"},{"key":"989_CR31","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/acr.23279","volume":"69","author":"L Buckley","year":"2017","unstructured":"Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J et al (2017) 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 69:1095\u20131110","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"989_CR32","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381","journal-title":"Osteoporos Int"},{"key":"989_CR33","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854\u2013865","journal-title":"Lancet"},{"key":"989_CR34","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1211\/jpp.60.12.0017","volume":"60","author":"Y Gao","year":"2008","unstructured":"Gao Y, Xue J, Li X, Jia Y, Hu J (2008) Metformin regulates osteoblast and adipocyte differentiation of rat mesenchymal stem cells. J Pharm Pharmacol 60:1695\u20131700","journal-title":"J Pharm Pharmacol"},{"key":"989_CR35","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.ejphar.2011.07.033","volume":"668","author":"C Sedlinsky","year":"2011","unstructured":"Sedlinsky C, Molinuevo MS, Cortizo AM, Tolosa MJ, Felice JI, Sbaraglini ML, Schurman L, McCarthy AD (2011) Metformin prevents anti-osteogenic in vivo and ex vivo effects of rosiglitazone in rats. Eur J Pharmacol 668:477\u2013485","journal-title":"Eur J Pharmacol"},{"key":"989_CR36","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.bone.2010.12.003","volume":"48","author":"WG Jang","year":"2011","unstructured":"Jang WG, Kim EJ, Bae IH, Lee KN, Kim YD, Kim DK, Kim SH, Lee CH, Franceschi RT, Choi HS, Koh JT (2011) Metformin induces osteoblast differentiation via orphan nuclear receptor SHP-mediated transactivation of Runx2. Bone 48:885\u2013893","journal-title":"Bone"},{"key":"989_CR37","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1055\/s-2007-992786","volume":"116","author":"L Schurman","year":"2008","unstructured":"Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM (2008) Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116:333\u2013340","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"989_CR38","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1007\/s00774-012-0374-0","volume":"30","author":"C Wang","year":"2012","unstructured":"Wang C, Li H, Chen SG, He JW, Sheng CJ, Cheng XY, Qu S, Wang KS, Lu ML, Yu YC (2012) The skeletal effects of thiazolidinedione and metformin on insulin-resistant mice. J Bone Miner Metab 30:630\u2013637","journal-title":"J Bone Miner Metab"},{"key":"989_CR39","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1196\/annals.1365.035","volume":"1092","author":"DJ Hadjidakis","year":"2006","unstructured":"Hadjidakis DJ, Androulakis II (2006) Bone remodeling. Ann NY Acad Sci 1092:385\u2013396","journal-title":"Ann NY Acad Sci"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-019-00989-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-00989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-019-00989-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T19:21:33Z","timestamp":1580412093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-019-00989-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["989"],"URL":"https:\/\/doi.org\/10.1007\/s00774-019-00989-y","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]},"assertion":[{"value":"30 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All the authors have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}